Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia Leukemia (2007) The phosphatidylinositol-3-kinase-Akt (PI3K-Akt) signalling pathway plays a critical role in regulating the cellular processes of growth, survival and differentiation. Constitutive activation of the pathway is recognized to be heavily implicated in the development of cancer. Mutation of members of the PI3K-Akt pathway is observed in up to 30% of all human cancers, and the PI3K-Akt pathway is constitutively active in primary acute myeloid leukaemia (AML) cells. Furthermore, constitutive Akt phosphorylation is linked to drug resistance and shortened overall survival in AML. Appropriate and timely negative regulation of the PI3K pathway is required to avoid constitutive signalling.
SH2-containing inositol 5 0 -phosphatase 1 (SHIP1) is a 145-kDa protein whose expression is restricted to haematopoietic cells. SHIP1 functions as a negative regulator of the PI3K--Akt pathway by hydrolysis of PIP 3 to PI-3,4-P 2 , and it may also play a significant role in regulating Akt membrane localization. Restoration of SHIP1 function to a human T-cell leukaemia cell line downregulates constitutively active Akt and causes delayed cellular transit through the G 1 phase of the cell cycle, restricting cell growth. SHIP1 levels are reduced in primary cells from CML patients and following induction of BCR-ABL. The SHIP1 knockout (À/À) mouse has a shortened lifespan and overproduces granulocytes and macrophages due to hyper-responsiveness of granulocyte/macrophage progenitors to a number of growth factors and cytokines. SHIP1 À/À mice suffer from splenomegaly and extramedullary haematopoiesis, and die from massive myeloid infiltration of the lungs. 1 Together, these findings indicate that the reduction or inactivity of SHIP1 may directly contribute to leukaemia pathogenesis. A single somatic missense phosphatase-domain mutation in INPP5D, the SHIP1 gene, was reported in 1 of 30 AML patients that reduced catalytic activity of SHIP1, 2 and a further seven missense INPP5D mutations were reported in 7 of 32 (22%) Chinese AML patients 3 ( Figure 1 ). These results suggest that SHIP1 mutations may contribute to the pathogenesis of AML, and thus also provide a novel therapeutic target.
We aimed to determine the incidence of INPP5D mutations in a cohort of 57 Caucasian AML patients, representing all eight French-American-British (FAB) subtypes (M0-M7), by denaturing high-performance liquid chromatography (DHPLC) and DNA sequencing. At the outset of our study, we noted that human INPP5D was poorly characterized in the literature and on genome databases. We therefore interpreted INPP5D gene structure based on alignment between INPP5D transcript (cDNA accession U57650) and human chromosome 2 assembled sequences. We found human INPP5D to consist of 27 exons, spanning a genomic region of at least 148 kb of chromosome 2q37.1 ( Figure 1 ). All 27 exons are flanked by canonical AG (acceptor) and GT (donor) splice sites. Exons range in size from 64 bp (exon 2) to 1196 bp (exon 27, including the 3 0 untranslated region (UTR), and introns (with the exception of intron 5, whose length is yet to be determined) from 125 bp to 42.7 kb. A small CpG island comprising 18 CpGs within a 227-bp region of the first exon was identified. In the absence of any evidence for an additional 5 0 untranslated exon, it appears that INPP5D is transcribed using a TATA-less promoter.
To identify potential SHIP1 mutations in Caucasian AML, genomic DNA was obtained from the peripheral leukocytes of 22 healthy controls, and from presentation bone marrow of 57 adult de novo AML cases, entered into the Medical Research Council (MRC) trials AML X and XII. Patients comprised the FAB subtypes M0 (n ¼ 5), M1 (n ¼ 10), M2 (n ¼ 10), M3 (n ¼ 10), M4 (n ¼ 10), M5 (n ¼ 10), M6 (n ¼ 1) and M7 (n ¼ 1). PCR was used to prepare DNA amplicons corresponding to all 27 exons and intron/exon boundaries of INPP5D. Amplicons were analysed by DHPLC using the Transgenomic WAVE system. To determine DHPLC sensitivity, DNA from healthy controls with known polymorphic genotype at two loci (INPP5D c.1037C4G and c.3563 þ 62_69dup8) was studied. DNA pools from two control individuals were constructed such that the rare allele at each locus was present at proportions of 1, 2, 5, 7, 10, 20, 30, 40 and 50% compared to the common allele. Pooled DNA samples were then amplified and amplicons subjected to DHPLC as described above. Potential sequence changes identified by altered DHPLC migration profile ( Figure 2 ) were characterized by bidirectional DNA sequencing. PCR amplicon sequences were compared to the deduced INPP5D genomic reference sequence, and sequence alterations were catalogued with reference to the SHIP1 cDNA (accession U57650).
No sequence changes detected in this cohort of AML patients (other than polymorphisms) corresponded to those reported in seven Chinese AML patients 3 ( Figure 1 ), and our data suggest that SHIP1 missense mutations are rare in Caucasian AML. We identified two non-synonymous translated sequence alterations:
(i) a previously characterized SNP (c.3501C4T; rs9247) predicting an exon 26 H1168Y alteration was identified in 16/57 AMLs (28%) and 6/22 (27%) healthy volunteers; (ii) a c.466G4A alteration in exon 4, predicted to cause an R156Q substitution, was identified in 1 of 57 AML patients but not in any of 22 healthy individuals. R156 is situated between SHIP1's SH2 and phosphatase domains and the specific residue and region in general show significant conserved homology between species (Figure 3) . It is not known whether this alteration represents a patient-specific mutation or rare polymorphism, nor is it known what biological significance this alteration may have, although the vast majority (83%) of missense mutations have been found to affect protein stability. 4 Should the R156Q alteration reduce SHIP1 catalytic activity or overall stability of the SHIP1 protein, increased phosphorylation of Akt and enhanced cellular proliferation could result. The possibility that the R156Q alteration may play a role in AML pathogenesis cannot, therefore, be ruled out. We could not obtain a subsequent sample from this patient for DNA sequence comparison pre-and postremission. We further identified six synonymous (non-amino-acid altering) single nucleotide alterations, of which four were novel and two were catalogued as polymorphic in dbSNP (http://www.ncbi.nlm.nih.gov/projects/ SNP). Five of these six changes were found in at least three healthy control samples, including the two previously characterized polymorphisms. The remaining c.3317G4A (Lys1106Lys) alteration was found in one AML patient, but not in any of the 22 healthy individuals. A total of 34 untranslated sequence alterations were identified in introns or 5 0 UTR or 3 0 UTR, of which 14 were reported on dbSNP. The majority of these alterations were identified in at least one healthy individual, although six were not. These six untranslated sequence alterations, c.198À30T4C, c.520 þ 37G4A, c.830 þ 19C4T, c.831À43C4T, c.2593À99G4A and c.
n 5C4T, were each found in one of 57 patients. Interestingly, the c.830 þ 19C4T and c.831À43C4T changes were common to the same individual patient; similarly, the c.2593À99G4A and c. affect splice site recognition using prediction software at http:// www.fruitfly.org/seq_tools/splice.html, although c.520 þ 37G4A may introduce an alternative donor site (score 0.48 for possible alternative vs 0.99 for our derived splice site).
On the basis of the high coding-region SHIP1 mutation rate previously identified (22%), 3 it was surprising that coding-region INPP5D mutations were not more common in our AML patient cohort. In this study, DHPLC detected a variant allele at X5% (data not shown) at both loci tested, well below the defined level of 430% bone marrow leukaemic blasts at diagnosis which characterizes AML. 5 It is, therefore, unlikely that our failure to confirm previously reported INPP5D changes associated with AML, or any other likely pathogenic INPP5D coding-region sequence changes, was due to technical limitations.
We considered whether differential acquisition rates of somatic mutations between ethnic groups may at least partially explain the different findings of this study compared to those previously reported in Chinese AML patients. Meta-analysis of 10 studies reported a significantly higher frequency of somatic epidermal growth factor receptor (EGFR) mutations in East Asians compared to non-Asians (33 vs 6%) in 2347 non-small cell lung cancer patients, correlating with ethnic response to the EGFR inhibitors gefitinib and erlotinib. 6 When limited to adenocarcinoma subtypes, almost half of the patients had EGFR mutations (270 of 563; 48%). Interestingly, of those adenocarcinomas in the United States and Australia with EGFR mutations, four of five (80%) were of East Asian ethnicity, while only 63 of 519 (12%) of others (mostly Caucasian) had mutations. This suggests that ethnic (genetic) differences are more important than geographical (environmental) differences, although the number of patients was small. Geographical/ ethnic-dependent mutation was similarly observed in 20 Sudanese breast cancer patients, in whom no p53 exon 5-9 mutations were detected using specified detection protocols, despite a reported incidence of 30-50% in Caucasian patients. 7 Furthermore, cytogenetic abnormalities are observed to occur at different incidences in AML patients depending on their ethnic group; the translocation t(15;17) occurs at a higher incidence of AML cases in South America and the Latin population of the Letters to the Editor USA and Spain compared to Caucasian AML cases, while t(8;21) is more common in Morocco, Tunisia and Japan. Together, these findings support a likely ethnic-dependent role for somatic mutation in cancer pathogenesis, and highlight the importance for clinical trials to include sufficient power to identify these differences.
The mRNA expression of SHIP1 was determined using the Affymetrix U133A GeneChip data set previously described 8 (GEO accession number GSE1159). INPP5D was represented by two probe sets, 203331_s_at and 203332_s_at on the GeneChip. All 285 primary AML cases showed equally high expression of INPP5D (Figure 4) . INPP5D was not specifically up-or downregulated in any of the FAB subtypes nor in the 16 subclasses of AML, which were defined on the basis of gene expression profiling 8 (data not shown). Interestingly, SHIP1 expression appeared to be significantly reduced in AML cells compared to control CD34 þ cells using probe set 203331_s_at (Student's twosample two-tailed t-test; Figure 4 ). However, this was not true where the probe set 203332_s_at was used, and furthermore, combined analysis of both probe sets indicated that SHIP1 mRNA expression levels in patients were similar to those found in control bone marrow mononuclear cells. Since different probe sets designed for particular genes do not always show equal performance, and CD34 þ cells may not represent the best control cell type, we suggest that INPP5D is unlikely to be specifically upor downregulated in AML cells compared to normal bone marrow.
We conclude that while coding-region SHIP1 mutations may play a role in the pathogenesis of AML among Chinese patients, in the Caucasian AML population, coding-region SHIP1 mutations are rare, and SHIP1 mRNA levels are not significantly altered. However, this study does not exclude dysregulated SHIP1 function at the protein level in primary AML cells as an important cause of AML. Furthermore, while we have identified eight novel patient-specific SHIP1 sequence alterations, we are uncertain to what extent and by what mechanism these alterations may mediate any possible pathogenic effect. 
